In total, we included 10,967 patients from TCGA and 10,945 patients from MSK, among which 1,661 patients were treated with ICI, for genomic analysis evaluating the prevalence of ROS1 mutation across various cancers (Figure 1). Here, ROS1 is linked to cancer.